Bioheart has announced successful completion of series D financing, that commenced on October 1, 2008, and through July 7, 2009. Bioheart has raised an amount of $2.8 million from the placement of restricted common stock and warrants under its current offering.
The maximum number of shares of Common Stock to be issued in connection with the Offering is 3,737,500 shares, of which 559,351 shares are remaining. The term of the Offering recently was extended through October 2009, said the company.
Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. The company’s pipeline includes multiple product candidates for the treatment of heart damage, including Bioheart Acute Cell Therapy, and MyoCell SDF-1.